Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gene Editing Deal Broadens Vertex's CF Base, Doubles CRISPR's Cash

This article was originally published in Scrip

Executive Summary

Vertex Pharmaceuticals made a big financial commitment to expand its cystic fibrosis portfolio beyond drugs for patients with specific genetic mutations to gene-editing therapies that may cure CF via a new partnership with CRISPR Therapeutics that more than doubles the startup firm's cash balance.


Related Content

CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?
IPO Update: Values Slip As Four More Biopharma Firms Go Public In October
Moderna Signs Single Drug Deal With CF Expert Vertex For Up To $315m


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts